Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Bayer's Asundexian?
Asundexian is a small molecule commercialized by Bayer, with a leading Phase III program in Ischemic Stroke. According to Globaldata,...
Risk adjusted net present value: What is the current valuation of Bayer's Asundexian?
Asundexian is a small molecule commercialized by Bayer, with a leading Phase III program in Acute Ischemic Stroke. According to...
Asundexian by Bayer for Myocardial Infarction: Likelihood of Approval
Asundexian is under clinical development by Bayer and currently in Phase II for Myocardial Infarction. According to GlobalData, Phase II...